OVERVIEW

• Facility area:
  • 495,700 ft² (46,000 m²)
• Commercial manufacturing area:
  • 410,700 ft² (38,100 m²)
• Regulatory approval:
  • U.S. FDA
  • U.S. DEA
• Pharmaceutical Development Services (PDS Cincinnati USA)
  • Pharmaceutical Development Services area: 85,000 ft² (7,900 m²)

Patheon’s Cincinnati Operations, USA, is fully equipped to handle high volume manufacturing for a wide range of solid and liquid dosage forms.

Ideal for high volume products, the facility houses state-of-the-art equipment with automated continuous processing and high speed packaging capabilities.

In addition to conventional dosage forms, Cincinnati Operations specializes in controlled release formulations as well as the development and manufacturing of Liquid-Filled Hard Capsules (LFHC), an ideal dosage form meeting the formulation challenges associated with low solubility or high-potency compounds.

Cincinnati Operations has been registered with the U.S. DEA for more than 30 years. With U.S. DEA manufacturing registrations (schedule II to V), analytical registrations (schedule I to V), and distribution registrations (schedule III to V), the facility is equipped to fully accommodate controlled drug product requirements.

The campus also contains an 85,000 ft² (7,900 m²) dedicated Pharmaceutical Development Services (PDS) facility offering our customers the convenience of advancing their development projects to market in one location. Please click on the PDS icon above to learn more about development services at PDS Cincinnati USA.